Thoracic Radiotherapy Improves the Survival in Patients With <i>EGFR</i> -Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial

H Hongfu Sun M Minghao Li (Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, 6−1 Kasuga-koen, Kasuga, Fukuoka 816-8580, Japan) W Wei Huang J Jian Zhang S Shihong Wei (Gansu Provincial Cancer Hospital, Lanzhou, China) Y Yongjing Yang (Department of Radiation Oncology, Jilin Cancer Hospital, Changchun, China) Z Zhongtang Wang (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China) S Shucheng Ye H Heyi Gong (Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China) Y Yaowen Zhang (State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry) J Jie Li H Haixia Song L Lifang Wang X Xiangming Chen (Department of Clinical Oncology, Taian City Central Hospital, Taian, China) H Haiqun Lin (Department of Oncology, the Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China) G Gaofeng Ding (Department of Radiation Oncolog, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China) H Hongwei Li (Peking University , , ,) A Anping Zheng (Department of Radiation Oncology, Anyang Cancer Hospital, Anyang, China) X Xuezhen Ma S ShaoShui Chen (Department of Radiation Oncology, Binzhou Medical University Hospital, Binzhou, China) L Liping Liu K Kaixian Zhang (Department of Radiation Oncology, Tengzhou Central People's Hospital, Tengzhou, China) C Chengrui Fu (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China) W Wenzhi Liu (Department of Radiation Oncology, Shenzhen Traditional Chinese Medicine Hospital, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China) J Jing Wang (Hunan Cancer Hospital Changsha China) X Xiaqin Zhang (Department of Radiation Oncology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/ Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China) T Tingting Liu D Dan Han (School of Materials Science and Engineering) Q Qian Zhao (Zhejiang University , , ,) P Peipei Wu (Cold Spring Harbor Laboratory) Q Qianqian Yuan L Lijun Tian P Ping Zhang X Xueqin Wu F Fei Chen Z Zicheng Zhang (College of Advanced Interdisciplinary Studies, National University of Defense Technology , Changsha 410073,) B Baosheng Li (Chongqing University , , ,)

Abstract

PURPOSE This multicenter, randomized, phase III clinical trial (Northern Radiation Oncology Group of China-002) focused on patients with oligo-organ metastatic non–small cell lung cancer (NSCLC) who have epidermal growth factor receptor ( EGFR ) mutations. We aimed to investigate whether first-line concurrent thoracic radiotherapy (TRT) and EGFR-tyrosine kinase inhibitors (TKIs), compared with TKIs alone, could achieve better survival. MATERIALS AND METHODS The patients in the TKI plus TRT group received 60 Gy to primary lung tumor and positive regional lymph nodes. Radiotherapy for metastases to other sites was determined by clinicians. The primary end point was the progression-free survival (PFS). Secondary end points included overall survival (OS) and treatment-related adverse events (TRAEs). The first and second interim analyses were performed in March 2021 and March 2022. RESULTS Between April 14, 2016, and February 25, 2022, a total of 118 patients were enrolled. Compared with the TKI alone group, the TKI plus TRT group achieved significantly better PFS (hazard ratio [HR], 0.57; P = .004) and OS (HR, 0.62; P = .029). The median PFS was 10.6 months in the TKI alone group and 17.1 months in the TKI plus TRT group. The median OS was 26.2 months and 34.4 months in the TKI alone group and TKI plus TRT group, respectively. The TKI plus TRT group showed better local control but was associated with a higher incidence of severe TRAEs (11.9% v 5.1%). CONCLUSION For patients with EGFR -mutated oligo-organ metastatic NSCLC treated with first-line EGFR-TKIs, concurrent TRT improves the PFS and OS, and TRAEs are acceptable and tolerable.

Article Details

Volume / Issue Vol. 43, Issue 4
Published February 01, 2025
Pages 412-421
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (37)

H

Hongfu Sun

M

Minghao Li

Interdisciplinary Graduate School of Engineering Sciences, Kyushu University, 6−1 Kasuga-koen, Kasuga, Fukuoka 816-8580, Japan

W

Wei Huang

J

Jian Zhang

S

Shihong Wei

Gansu Provincial Cancer Hospital, Lanzhou, China

Y

Yongjing Yang

Department of Radiation Oncology, Jilin Cancer Hospital, Changchun, China

Z

Zhongtang Wang

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China

S

Shucheng Ye

H

Heyi Gong

Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China

Y

Yaowen Zhang

State Key Laboratory of Inorganic Synthesis and Preparative Chemistry, College of Chemistry

J

Jie Li

H

Haixia Song

L

Lifang Wang

X

Xiangming Chen

Department of Clinical Oncology, Taian City Central Hospital, Taian, China

H

Haiqun Lin

Department of Oncology, the Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China

G

Gaofeng Ding

Department of Radiation Oncolog, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

H

Hongwei Li

Peking University , , ,

A

Anping Zheng

Department of Radiation Oncology, Anyang Cancer Hospital, Anyang, China

X

Xuezhen Ma

S

ShaoShui Chen

Department of Radiation Oncology, Binzhou Medical University Hospital, Binzhou, China

L

Liping Liu

K

Kaixian Zhang

Department of Radiation Oncology, Tengzhou Central People's Hospital, Tengzhou, China

C

Chengrui Fu

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China

W

Wenzhi Liu

Department of Radiation Oncology, Shenzhen Traditional Chinese Medicine Hospital, the Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, China

J

Jing Wang

Hunan Cancer Hospital Changsha China

X

Xiaqin Zhang

Department of Radiation Oncology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/ Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China

T

Tingting Liu

D

Dan Han

School of Materials Science and Engineering

Q

Qian Zhao

Zhejiang University , , ,

P

Peipei Wu

Cold Spring Harbor Laboratory

Q

Qianqian Yuan

L

Lijun Tian

P

Ping Zhang

X

Xueqin Wu

F

Fei Chen

Z

Zicheng Zhang

College of Advanced Interdisciplinary Studies, National University of Defense Technology , Changsha 410073,

B

Baosheng Li

Chongqing University , , ,